Tag:
Qsymia
Latest Headlines
Latest Headlines
Battle of weight-loss drugs begins as Arena launches Belviq next week
The long-awaited battle between two weight loss drugs is ready to begin. With its launch for Belviq delayed by the DEA, Arena has had to sit back and watch competitor Vivus pass it by with its own weight-loss drug. Now, nearly a year after the FDA cleared Belviq for approval, investors will get the chance to see if it can outperform its underwhelming competitor, Qsymia.
Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board
A Vivus shareholder who wants to stack the drugmaker's board with a more aggressive slate of directors has brought in one of the champions of this kind of shareholder brawl. Alex Denner, who gained his experience in proxy fights as the head of Carl Icahn's healthcare investments, has been invited to the battle by investor First Manhattan Co.
After going it alone, Vivus finally open to Big Pharma sales partnership
Vivus' announcement that the company is looking to partner with Big Pharma for marketing help to get its new weight-loss drug, Qsymia, off the ground apparently encouraged investors. Shares rose 9.7% to $13.21, the biggest one-day increase since Dec. 17, Bloomberg reported.
Arena pulls app for weight-loss drug Belviq in EU
Arena Pharmaceuticals has decided to take its drug application and go home. The drugmaker Friday said it was giving up for now on breaking through the European wall of resistance to its weight-loss drug Belviq. The company, which got FDA approval last year, yanked its application with little explanation.
Vivus clears one of many hurdles for new weight drug
The FDA has agreed to take down one of the big hurdles hampering U.S. sales of Vivus' newly approved weight drug Qsymia, but plenty more remain.
Vivus revs up new Qsymia sales plan after FDA removes a roadblock
The FDA has agreed to take down one of the big hurdles hampering U.S. sales of Vivus' newly approved weight drug Qsymia, but plenty more remain.
Vivus investor says FDA move on Qsymia isn't enough
At least one Vivus shareholder isn't convinced that loosening FDA restrictions on a new obesity pill will fuel sales in any significant way. First Manhattan, which owns a 9.1% stake in the drugmaker, said that modifications to Qsymia's risk-management plan are "necessary"--but they're "not sufficient" for its success.
Analysts rank the top 10 blockbuster duds in biopharma
Let's face it: When it comes to new drug approvals, projected blockbuster revenue is one of the sexiest aspects of the story. So when Biogen Idec's new Tecfidera was approved for multiple sclerosis, the main competition was seen in bidding up what the drug is likely to bring in for the Boston-based biotech. And the numbers soared to full mega-blockbuster status.
Vivus hopes weight-loss app will fatten up Qsymia sales
Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try.
Vivus hopes weight-loss app will fatten up Qsymia sales
Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try.
